Evaluation of Anthelmintic Properties and Toxicity of Pure Compounds Isolated from Dalea Spp (Plantae, Fabaceae) by McPherson, Victoria LH
Central Washington University
ScholarWorks@CWU
All Master's Theses Master's Theses
Fall 2018
Evaluation of Anthelmintic Properties and Toxicity
of Pure Compounds Isolated from Dalea Spp
(Plantae, Fabaceae)
Victoria LH McPherson
Central Washington University, mcphersonv@cwu.edu
Follow this and additional works at: https://digitalcommons.cwu.edu/etd
Part of the Natural Products Chemistry and Pharmacognosy Commons, and the Parasitic
Diseases Commons
This Thesis is brought to you for free and open access by the Master's Theses at ScholarWorks@CWU. It has been accepted for inclusion in All Master's
Theses by an authorized administrator of ScholarWorks@CWU. For more information, please contact scholarworks@cwu.edu.
Recommended Citation
McPherson, Victoria LH, "Evaluation of Anthelmintic Properties and Toxicity of Pure Compounds Isolated from Dalea Spp (Plantae,
Fabaceae)" (2018). All Master's Theses. 1102.
https://digitalcommons.cwu.edu/etd/1102
EVALUATION OF ANTHELMINTIC PROPERTIES AND TOXICITY OF PURE COMPOUNDS 
ISOLATED FROM DALEA SPP (PLANTAE, FABACEAE). 
 
 
__________________________________ 
 
 
 
A Thesis 
 
Presented to 
 
The Graduate Faculty 
 
Central Washington University 
 
 
 
___________________________________ 
 
 
 
In Partial Fulfillment 
 
of the Requirements for the Degree 
 
Master of Science 
 
Biology 
 
 
 
___________________________________ 
 
 
 
by 
 
Victoria LH McPherson 
 
November 2018 
 ii 
CENTRAL WASHINGTON UNIVERSITY 
 
Graduate Studies 
 
 
 
 
We hereby approve the thesis of 
 
 
Victoria LH McPherson 
 
 
Candidate for the degree of Master of Science 
 
 
 
 
 
     APPROVED FOR THE GRADUATE FACULTY 
 
 
______________  _________________________________________ 
    Dr. Blaise Dondji, Committee Chair 
 
 
______________  _________________________________________ 
    Dr. Gil Belofsky 
 
 
______________  _________________________________________ 
    Dr. Gabrielle Stryker 
 
 
______________  _________________________________________ 
    Dean of Graduate Studies 
     
 
 
 
 
 
 iii 
ABSTRACT 
EVALUATION OF ANTHELMINTIC PROPERTIES AND TOXICITY OF PURE COMPOUNDS 
ISOLATED FROM DALEA SPP (PLANTAE, FABACEAE). 
 
by 
 
Victoria LH McPherson 
 
November 26, 2018 
 
Infecting upwards of a billion people worldwide, hookworm is one of the most 
prevalent parasitic infections affecting the world today. Those infected experience 
hookworm disease, characterized by severe anemia, which can lead to malnutrition, 
low birth weights, and physical and mental impairments. Currently, the 
benzimidazoles albendazole and mebendazole are used as the primary treatment; 
however, resistance to these drugs is emerging. Due to this resistance, finding new 
anthelmintic compounds active against hookworm is a priority. Previously, a pure 
compound isolated from Dalea ornata was identified as having strong anthelmintic 
activity when used against the hookworm Ancylostoma ceylanicum. This project was 
continued using pure compounds isolated from Dalea pogonathera and D. parryi. 
The pure compounds were tested for toxicity and anthelmintic properties. The 
structure of these compounds were determined using NMR. To test toxicity, spleen 
cells were obtained from Golden Syrian hamsters, Mesocricetus auratus, which were 
then exposed to 50µg/mL of compound for 24 hours to determine whether the 
compound induces apoptosis. This was done by analyzing the cells after the 24 hour 
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incubation using flow cytometry to compare cell survival from the experimental cells 
to the controls. An ex vivo assay was employed to test for anthelmintic properties by 
exposing adult A. ceylanicum to 50µg/mL of compound for 5 days, monitoring 
motility and mortality. Unfortunately, none of the pure compounds tested were 
active towards A. ceylanicum; however, the methods used can be replicated for 
similar projects. 
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CHAPTER 1 
 
INTRODUCTION 
 
Hookworm Epidemiology  
 
Hookworm is one of the most prevalent parasitic infections in the world 
today. Infecting an estimated billion people worldwide, hookworm is an endemic 
infection in Africa, China, Southern Asia, and South America, with 240 million people 
being infected in Sub-Saharan Africa alone (Hotez et al. 2004; Brooker et al. 2010). 
Furthermore, an estimated 5.08 billion people are at risk, with 1 billion of those 
being school-aged children (Pullan and Brooker 2012). These infections are 
responsible for around 4 million disability adjusted life years (DALYs) and an 
economic loss of up to $139 billion dollars (Bartsch et al. 2016). The hookworm 
species responsible for causing these infections in humans are Necator americanus 
and Ancylostoma duodenale, with occurrences of a zoonotic infection of 
Ancylostoma ceylanicum (de Silva et al. 2003; Hotez et al. 2004; Brooker et al. 2010; 
Ngui et al. 2012). Depending on the worm burden, specifically the number of adult 
worms residing in the small intestine, the infection can cause hookworm disease, 
which is characterized by its primary symptom of iron-deficiency anemia (Guyatt et 
al. 2000; Crompton and Nesheim 2002; Humphries et al. 2011). This anemia is 
caused by hookworms feeding on blood while it resides in the host’s small intestine. 
The adult hookworm latches on to the endothelial cells of the small intestine via its 
buccal capsule and creates negative pressure to feed off of the flow of blood and 
plasma, producing anticoagulant secretions that inhibit the function of platelets 
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(Cappello et al. 1996, Chadderdon and Cappello 1999, Del Valle et al. 2003). If the 
amount of blood lost is greater than that which is being produced, the end result is 
anemia and hypoproteinemia, an abnormally low level of protein in the blood 
(Crompton and Nesheim 2002). 
The most at risk for this infection are those living in poverty with minimal 
sanitation (Hotez 2008; Humphries et al. 2011). This disease is spread rapidly 
through communities because it is primarily transmitted through contact with soil 
contaminated by feces, although, for Ancylostoma species an oral route of 
transmission can occur (Ngui et al. 2012). Although all people living in poverty in an 
endemic area are at risk for the disease, children and pregnant women are the most 
at risk for complications associated with hookworm disease. Iron-deficiency anemia 
and hypoproteinemia are associated with stunting growth both physically and 
mentally in children (Sakti et al. 1999; Guyatt et al. 2000), malnutrition (Crompton 
and Nesheim 2002; Hotez et al. 2004), and pregnancy complications such as low 
birth weight and impairment of milk production (Santiso 1997).  Although mortality 
rates for hookworm infection are low, there have been a few studies suggesting 
chronic hookworm infection increases the susceptibility of the host to other 
infections such as malaria (Mwangi et al. 2006; Humphries et al. 2011), tuberculosis 
(Potian et al. 2011), and HIV (Borkow et al. 2007; Walson and John-Stewart 2007).  
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Hookworm Life Cycle 
While residing in the small intestine, female hookworms produce 
approximately 30,000 eggs per day, varying with species, which then leave the body 
in feces. The eggs hatch, the larvae molt twice, and then become infective during 
their third stage (L3). At this stage they produce proteases allowing them to 
penetrate the skin (Loukas et al. 2005), most commonly being the palms of hands 
and the soles of feet, get into the blood stream, and make their way to the lungs. 
While in the lungs, the L3 are coughed up into the trachea, swallowed, and then 
arrive at the small intestine. This is where the larvae mature into adult hookworms, 
feed, release eggs, and begin the cycle once more (Figure 1). During the act of 
feeding, adult hookworms continue to be motile in the small intestine, moving every 
4-6 hours after feeding at a single spot, resulting in a blood loss of about 0.02-0.2 mL 
of blood per worm per day (Sakti et al. 1999). This loss of blood can result in the 
primary symptom of hookworm disease, iron-deficiency anemia.  
 4 
 
Figure 1.1. The Life Cycle of Hookworm. 
Depicted is the life cycle of hookworm, starting at the egg released in the feces (1) 
until the maturation from larva to adult worm in the small intestine (CDC 2013). Not 
pictured is the second route of infection, oral transmission. 
 
Hookworm Immunology 
As with most pathogens, hookworm infection elicits an immune response. To 
clear a hookworm infection, it is necessary for the adaptive immune response to be 
activated, which involves the maturation of CD4+ T lymphocytes. Specifically, a T 
helper 2 (TH2) response is required. A TH2 response is one of the subsets of the 
adaptive immune response characterized by the activation and differentiation of B 
cells into plasma cells. Plasma cells have the ability to produce and secrete antigen 
specific antibodies, proteins that can bind to antigens and activate other cells of 
immunity. To successfully clear a hookworm infection, IgE must be produced and 
basophils, eosinophils, and mast cells need to be activated (Quinnell et al. 2005; 
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Loukas et al. 2005; McSorley and Loukas 2010; Urb and Sheppard 2012). In response 
to a hookworm infection, interleukin-4 (IL-4) is secreted by basophils that have 
either acquired antigen or in the presence of dendritic cells acting as antigen 
presenting cells, initiating a TH2 response by causing the differentiation of naïve T 
cells to TH2 cells while also preventing a TH1 dominant response (Gaze et al. 2012; 
Yoshimoto 2018). A TH1 response is not necessary and would not aid in hookworm 
clearing because it involves the activation of macrophages, phagocytic cells, that are 
unable to engulf hookworm due to their large size. The activated TH2 cells then 
secrete IL-5 and IL-13, which activate eosinophils and facilitates the secretion of IgE 
respectively (Gaze et al. 2012). Secreted IgE will then bind to the hookworm antigen 
using the variable region of its structure, leaving the constant region (Fc) to be 
bound by eosinophils or mast cells. Once bound, eosinophils and mast cells will 
release cytokines and reactive oxygen species that are toxic to the hookworm and 
eventually result in death. This immune response generally occurs in the blood, 
during the larval hookworm’s migration. Once in the small intestine, the antibody 
IgA contributes to the mucosal immune response. Involved with protecting mucosal 
surfaces, such as the small intestine, IgA is potentially responsible for the 
neutralization of hookworm secretions, initiation of eosinophil degranulation, and 
can interfere with hookworm feeding (Bungiro et al. 2008; Moreau and Chauvin 
2010). 
However, hookworm does have methods to evade the immune system. One 
of the first evasion tactics employed is antigenic shedding. It is believed that 
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hookworm larva is covered in a larval sheath that they cast once they have infected 
a host to distract the immune system (Kumar and Pritchard 1992). Instead of 
preventing an immune response, it uses the distraction of an immune response to 
complete the migration to the small intestine. Although the mechanism is not 
known, it has also been shown that hookworm reduce dendritic cell differentiation 
and suppresses the proliferation of antigen presenting cells in general (Dondji et al. 
2008; Passos et al. 2017). As mentioned previously, dendritic cells are integral to the 
activation of the adaptive immune system and, by preventing their differentiation, 
the immune response is slowed. Hookworm also has been shown to suppress and 
induce apoptosis in CD4+ T cells (Chow 2000; Dondji et al. 2010; Morawski et al. 
2017). Another way hookworm disrupts the TH2 response is to induce Natural Killer 
cells (NK cells). This induction allows NK cells to produce interferon-γ, which is a 
cytokine involved with the upregulation and maintenance of a TH1 response 
(Bethony et al. 2006). Besides preventing a TH2 response from occurring, hookworm 
can also reduce the effect of a TH2 response. One of the mechanisms behind this is 
the production of proteases. Hookworms have been shown to produce proteases 
that cleave the Fc region of antibodies (Pritchard 1995). This means that the 
antibodies can bind to the antigen, but not allow the activation of eosinophils or 
mast cells, thereby saturating the antibody binding regions with ineffective 
antibodies. Hookworm can also produce metalloproteases, which cleave eotaxin, a 
protein that recruits eosinophils to the site of infection (Culley et al. 2000). Along 
with proteases, hookworm also release excretory/secretory (ES) proteins. These 
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proteins have been shown to induce a hookworm-like immune response, even when 
hookworm is not present. They upregulate nitric oxide production, which impacts 
lymphocyte proliferation, IL-12, and interferon-γ, while decreasing IgG and IL-4, 
impairing the TH2 response (Dondji et al. 2008; Diliani and Dondji 2017). ES is also 
hypothesized to induce a specific dendritic cell phenotype, one that is tolerogenic 
(Logan et al. 2018). Tolerogenic dendritic cells, specifically CD103+ dendritic cells, 
are responsible for maintaining homeostasis in the intestinal mucosa. They are 
induced by the production of IL-10 from TH2 T cells and activate FoxP3+ T regulatory 
cells (Treg). The primary function of tolerogenic dendritic cells and Treg cells is to 
modulate the immune system by immunosuppression. Essentially, they produce 
anti-inflammatory cytokines like those of IL-10 and TGF-β that prevent the 
differentiation and proliferation of naïve T cells into effector T cells (Ricci et al. 
2011). Related to this is the activation and polarization of M2 macrophages. 
Damaged epithelial cells release IL-33, which propagates Treg and M2 macrophage 
differentiation, to begin immunosuppression and a healing response (Gordon and 
Martinez 2010; Takenaka and Quintana 2017; Schwartz et al. 2018). By activating 
cells of immunity involved in suppression, hookworm prevent an immune response 
by invoking self-tolerance. This mechanism of enforcing self-tolerance is one of the 
reasons those chronically infected with hookworm do not have allergies. This effect 
is also amplified in the lungs during larval migration, which is hypothesized to be the 
mechanism responsible for the decrease in asthma in those infected (Schwartz et al. 
2018). Lastly, as previously mentioned, hookworm needs a steady flow of blood to 
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feed. To do this, they produce anticoagulants to inhibit and prolong the period of 
time it takes for blood to clot (Schuster et al. 2013). 
 
Current Treatment Methods 
Current treatment of hookworm infection is completely reliant on the use of 
benzimidazole anthelmintics, specifically mebendazole (MBZ) or albendazole (ABZ), 
distributed following the deworming campaigns endorsed by the World Bank and 
World Health Organization (WHO 2001; World Bank 2003). These campaigns call for 
mass drug administration to high-risk groups (school-aged children). Although cure 
rates following single dose regiments previously were recorded as high as 100%, 
newer studies suggest this number is much lower, with a failure rate of 39-56% 
(Humphries et al. 2011; Humphries et al. 2013). A recent study conducted by 
Palmeirim et al. compared a single dose treatment of 500mg to three doses of 
100mg mebendazole against soil-transmitted helminths. The cure rate of the single 
dose treatment was drastically lower, 13%, compared to the 97.9% cure rate of the 
multiple dose treatment (Palmeirim et al. 2018). Unfortunately hookworm was not 
present as one of the soil-transmitted helminths included in this clinical trial. 
However, in a study including hookworm, the cure rate was 25.5% for a single dose 
of 500mg mebendazole (Mrus et al. 2018). With the need to use multiple doses, 
concerns have been raised about the selective pressure put on hookworm and 
potential resistance arising from it. This is significant especially given the high failure 
rates of recent field studies, suggesting resistance may be emerging (Furtado et al. 
 9 
2016).  
Using MBZ and ABZ may treat the infection, but they do not provide lasting 
immunity to hookworm infection. This means that even if the treatment is 
successful, the rate of re-infection still remains high (Albonico et al. 1995). This is 
why an attempt at a hookworm vaccine occurred, to decrease the rate of re-
infection (Hotez et al. 2013). However, despite the high hopes for the success of the 
trial, the vaccine trial was halted due to the allergic reactions occurring in those 
previously exposed to hookworm after administration. The same research group has 
recently modified the vaccine by changing the target. Instead of using a larval 
protein, the vaccine target is now an adult hookworm protein belonging to N. 
americanus, Glutathione – S – Transferase (Na-GST-1) (Diemert et al. 2017). It is 
important to note that the vaccine target does differ from MBZ and ABZ’s target. 
The benzimidazoles prevent the formation of microtubules which prevents or 
minimizes the uptake of glucose. Without glucose, the hookworm is unable to 
produce ATP and eventually dies. The Glutathione – S – Transferase on the other 
hand targets the feeding behavior of hookworm by preventing the detoxification of 
reactive oxygen species. Hookworms digest blood by breaking it down into smaller 
molecules such as heme and hematin. Both of these molecules can generate 
reactive oxygen species which are toxic to the hookworm (Diemert et al. 2017). If 
successful, this vaccine would treat hookworm rather than prevent larval migration. 
Another vaccine in development is a cysteine protease inhibitor K11777, which has 
shown a promising effect in increasing the mortality of larvae and adult A. 
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ceylanicum hookworms (Vermeire et al. 2016). 
 
Anthelmintic and Antiparasitic Natural Products 
Using natural products to treat infection and disease is not a novel concept. 
There is evidence that natural products have been used in ancient civilizations such 
as the Egyptians and Mesopotamians, with the earliest written record of plant-based 
therapies dating back to 2600 BCE (Dias et al. 2012). Currently, around 80% of the 
world’s population is reliant on natural products for their primary healthcare (Ekor 
2013). Along with general malaise, plant compounds have also been used to treat 
parasitic infections. Artemotil, a derivative of artemisin, is a compound isolated from 
Artemisia annua that has anti-malarial properties (Dias et al. 2012). Also belonging 
to the Artemisia family, Artemisia parviflora and Artemisia siversiana have 
anthelmintic properties active against the nematode Haemonchus contortus. At 
12.5mg/mL, the A. parviflora extract killed over 60% of adult worms and over 50% of 
L3 larva. At 25mg/mL, the A. siversiana extract killed over 60% of adult worms and 
L3 larva (Irum et al. 2017). Another compound found to have anthelmintic 
properties is in Eucalyptus globulus, which has activity against nematodes in goats. 
Using a 7.5mg/kg dosage, a 66% reduction in the fecal egg count was recorded 21 
days post-treatment (Kanojiya et al. 2015). Lastly, an extract from Combretum 
mucronatum was active against Caenorhabditis elegans, a non-pathogenic 
nematode, causing a mortality rate of 58% at 1mg/mL (Agyare et al. 2014). Dalea 
spp. are plants of interest due to their already documented medicinal properties, 
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such as D. versicolor’s ability to enhance the activity of antibiotics against resistant 
bacterium (Belofsky et al. 2004) and D. elegans’ antioxidant properties (Elingold et 
al. 2008). A recent study published from the Dondji and Belofksy labs at Central 
Washington University indicated that tephrosin, a Dalea ornata isolate, had 
anthelmintic properties against the hookworm Ancylostoma ceylanicum (Table 1). 
After exposing adult worms to 25µg/mL of tephrosin (compound 10), all were dead 
after 72 hours (Deardorff et al. 2016). However, tephrosin is also highly toxic, 
making it unusable as a therapy for now. To continue this project, compounds 
isolated from Dalea parryi and Dalea pogonathera were evaluated for anthelmintic 
properties and toxicity. 
Table 1.1. Ex Vivo Anthelmintic Activity of D. ornata Compounds 1-10 Toward A. 
ceylanicum. 
With a concentration of 25µg/mL, compound 10, tephrosin, had killed 97% of 
hookworms after 48 hours. By 72 hours, all of the worms were dead (Deardorff et al. 
2016). Through this experiment, Tephrosin exhibited anthelmintic properties and 
was very active against A. ceylanicum. 
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CHAPTER 2 
 
THE EVALUATION OF TOXICITY AND ANTHELMINTIC PROPERTIES OF PURE 
COMPOUNDS ISOLATED FROM DALEA POGONATHERA 
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ABSTRACT 
 
Infecting around 1 billion people, hookworm is one of the most prevalent 
parasitic infections. Chronic infection can lead to severe anemia, malnutrition, and 
increased susceptibility to other infections. The current treatments used are the 
benzimidazole derivatives, mebendazole and albendazole. Although previously 
successful, emerging resistance has been reported and the need to identify new 
anthelmintic compounds is high. Pure compounds were isolated from Dalea 
pogonathera using various techniques such as vacuum liquid and thin layer 
chromatography. The structure of these compounds were then identified using NMR 
and used in toxicity assays to determine whether they induced apoptosis in the 
spleen cells of Golden Syrian hamsters, Mesocricetus auratus. Of the 16 compounds 
tested at 50μg/mL, 7 were non-toxic and the remaining 10 ranged from slightly toxic 
to toxic. The compounds were also tested in an ex vivo assay to determine if 
anthelmintic properties were present. Monitored for motility and mortality at 
50μg/mL for five days, none of the 16 compounds were significantly active against 
adult Ancylostoma ceylanicum.  
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Being one of the most prevalent parasitic infections to date, hookworm 
infects roughly a billion people worldwide. It is endemic in Africa, Southern and 
Southeast Asia, and Central and South America, with an increasing prevalence in 
areas of rural poverty.1 The hookworms Necator americanus, Ancylostoma 
duodenale, and Ancylostoma ceylanicum are those responsible for the majority of 
human infections; however, there are some accidental infections most commonly 
associated with dog hookworms such as Ancylostoma caninum.2-6 When infected, 
the hosts release feces containing eggs that will hatch in a warm and moist 
environment, releasing larva. The larva will then undergo two molts, becoming the 
infective L3 larva. The L3 are able to pierce through the skin, use the bloodstream to 
travel to the lungs where it causes irritation. This irritation causes the host to cough, 
bringing the larva into the trachea where it is then swallowed, eventually bringing 
them to the small intestine where the L3 mature into adult hookworms. As adults, 
the hookworms latch onto the endothelial cells lining the small intestine using their 
buccal capsules and feed off the flow of blood and plasma, producing anticoagulant 
secretions that inhibit the function of platelets.6-10 During the act of feeding, adult 
hookworms continue to be motile in the small intestine, moving every 4-6 hours 
after feeding at a single spot, resulting in a blood loss of about 0.02-0.2 mL of blood 
per worm per day.10 Depending on the hookworm burden, this can cause anemia, 
the primary symptom of hookworm disease.11 A. duodenale and A. ceylanicum also 
have an oral route of transmission, involving the direct ingestion of L3 larva from the 
environment. 
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Although all living in endemic areas are at risk for infection, those living in 
poverty have an increased prevalence of disease.12,13 The most at risk for 
complications are pregnant women and children. Iron-deficiency anemia and 
hypoproteinemia are associated with stunting growth both physically and mentally 
in children, malnutrition, and pregnancy complications such as low birth weight and 
impairment of milk production.1,10,11,14,15 Chronic infection is also associated with 
reduced lymphocyte proliferation and increased apoptosis of CD4+ T cells and an 
increase in nitric oxide production.16-18 More recently, hookworm and other soil-
transmitted helminths have been discovered to activate tolergenic dendritic cells, T 
regulatory cells, and M2 macrophages.19-23 All of these cell types promote self-
tolerance, inhibiting the immune response. This regulation of the immune response 
may be responsible for the increased susceptibility of those chronically infected to 
tuberculosis, HIV, and malaria.13,24-27  
Currently, the primary drugs used to treat hookworm infection are the 
benzimidazole derivatives, mebendazole (MBZ) and albendazole (ABZ). Following the 
World Health Organization and World Bank’s deworming campaign, the mass drug 
administration of single-dose MBZ and ABZ were widely distributed to high-risk 
groups.28,29 Although cure rates following single dose regiments previously were 
recorded as high as 100%, newer studies suggest this number is much lower, with a 
failure rate of 39-56% seen in field studies.13,30 A recent study conducted by 
Palmeirim et al. compared a single dose treatment of 500mg to three doses of 
100mg mebendazole against soil-transmitted helminths. The cure rate of the single 
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dose treatment was drastically lower, 13%, compared to the 97.9% cure rate of the 
multiple dose treatment.31 Unfortunately hookworm was not present as one of the 
soil-transmitted helminths included in this clinical trial. However, in a study including 
hookworm, the cure rate was 25.5% for a single dose of 500mg mebendazole.32 With 
the need to use multiple doses, concerns have been raised about the selective 
pressure put on hookworm and potential resistance arising from it.33 This is 
significant especially given the high failure rates of recent field studies, suggesting 
resistance may be emerging.13,30,31 New potential candidates with a different 
mechanism of action than the benzimidazoles are desirable. 
Dalea, a plant genus belonging to the Fabaceae family, is native to the New 
World. Dalea spp. have been previously shown to have medicinal purposes such as 
increasing the activity of antibiotics and antioxidant properties.35,36 Tephrosin, a 
pure compound isolated from Dalea ornata, is very active against adult A. 
ceylanicum, causing the mortality of all of the worms by day three of an ex vivo 
trial.34 However, tephrosin is also toxic, making it unusable as a therapy for now. 
Due to the identification of an active compound, Dalea spp. are still of interest. To 
continue this work, Dalea pogonathera, native to Arizona, New Mexico, and Texas, 
has been evaluated for the presence of anthelmintic isolates.  
 
Results and Discussion 
After the D. pogonathera extracts were purified via linear solvent gradient 
chromatography (Figure 1), two bioassays were completed to determine the toxicity 
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against splenocytes acquired from Golden Syrian hamsters, Mesocricetus auratus, 
and evaluate the anthelmintic properties towards A. ceylanicum.  
 
Figure 2.1. Structures of D. pogonathera Compounds 1-11, 16 
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Table 2.1. Toxicity of D. pogonathera Compounds 1-16 at 50μg/mL 
Relative to No Treatment Control 
compound 
% 
compound 
live cells 
% control 
live cells 
toxicity 
1 47.2 33.1 Non-toxic* 
2 0.31 40.5 Toxic* 
3 0.31 40.5 Toxic* 
4 7.65 29.8 Toxic* 
5 24.7 38.6 Toxic* 
6 34.8 34.1 Non-toxic 
7 0.66 34.9 Toxic* 
8 0.13 34.9 Toxic* 
9 9.3 36.5 Toxic* 
10 0.4 36.5 Toxic* 
11 0.53 36.5 Toxic* 
12 0.17 36.5 Toxic* 
13 44.9 52.2 Non-toxic 
14 51 52.2 Non-toxic 
15 55.5 52.2 Non-toxic 
16 77.2 66.9 Non-toxic* 
*Statistically significant difference 
 
 
Comparing the percentages of live cells of 106 cells of the 50μg/mL treated wells to 
that of the no treatment wells containing 2% DMSO using flow cytometry, the 
toxicity of each compound was determined (Table 1). The toxicity, for the context of 
this paper, is defined as the percentage of live cells in the experimental wells being 
statistically significantly lower than the percentage of live cells from the control 
wells. Compounds 1, 6, and 13-16 were all non-toxic, with compounds 1 and 16 
actually performing significantly better than the control, acting potentially as 
mitogens. The reason for this increased percentage of live cells was not investigated; 
however, all of the compounds that were non-toxic are promising potential 
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therapies. The remaining compounds were found to be toxic, with some, like 
compounds 2 and 12, devastatingly so, with a percentage of live cells of 0.31% and 
0.17% respectively.  
 All of the compounds were then tested using an ex vivo assay to evaluate the 
anthelmintic properties the compounds had towards adult A. ceylanicum (Table 2, 
Figure 1). Unfortunately, none of the compounds exhibited any significant 
anthelmintic activity. Compound 4 had the most activity with a mean mortality rate 
of 87.5%, followed by compound 8 with 91.7% (±7.2).  
Table 2.2. Ex Vivo Anthelmintic Activity of D. pogonathera Compounds 1-16 toward 
A. ceylanicum 
 % survival of A. ceylanicum relative to control at 50μg/mL   
compound day 1 day 2 day 3 day 4 day 5 
1 100 100 100 100 100 
2 100 100 100 100 100 
3 100 100 100 100 100 
4 100 100 100 100 87.5 (±0) 
5 100 100 100 100 91.7 (±14.4) 
6 100 100 100 100 100 
7 100 100 100 95.8 (±7.2) 91.7 (±7.2) 
8 100 100 100 100 100 
9 100 100 100 100 100 
10 100 100 100 100 100 
11 100 100 100 100 100 
12 100 100 100 100 95.8 (±7.2) 
13 100 100 100 100 95.8 (±7.2) 
14 100 100 100 100 100 
15 100 100 100 100 95.8 (±7.2) 
16 100 100 100 100 100 
aData in the table are in mean values ± standard error. 
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Figure 2.2. Percent Survival of Hookworm on Day 5 of Ex Vivo. 
 
 Although none of the compounds isolated from D. pogonathera were active 
toward A. ceylanicum, the methods used are applicable for similar research involving 
the screening of compounds. Aside from the biological components, compounds 4 
and 8 are novel compounds that have not been structurally identified or added to 
databases before. It would be interesting to investigate whether these compounds 
have other medicinal properties not tested in the scope of this paper despite their 
toxicity.  
Being considered one of the World Health Organization’s neglected tropical 
diseases, the need to identify new compounds active toward hookworm is great and 
more research in developing treatments is necessary, such as the work toward a 
hookworm vaccine.37 Not only is this work relevant to areas of high prevalence, but 
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also to the recently reported reemergence of hookworm in the Southern United 
States.38 Hookworm effects over a billion people at a given time, identifying a new 
active compound is just one step toward eradicating hookworm disease. 
 
Experimental Section 
Plant Material. Whole plants of D. pogonathera were collected by G. Belofsky in 
Southeast Arizona.  
Extraction and Isolation. The aerial portions of D. pogonathera were extracted using 
methanol, blended, filtered, and the filtrates were evaporated. The crude extract 
was then fractionated using vacuum liquid chromatography and Sephadex LH-20 
chromatography. The fractions created were pooled using thin layer 
chromatography. To separate these fractions into pure compounds, linear solvent 
gradient chromatography was used. 13C NMR spectroscopy was used to determine 
structure and confirm that each compound obtained was unique. 
Animals. All animals used in the following experiments were Golden Syrian hamsters 
(Mesocricetus auratus) housed at Central Washington University (CWU), with some 
being obtained from Simonsen Laboratories (Gilroy, CA, USA). The experiments 
conducted were approved by the CWU Institutional Animal Care and Use Committee 
(Protocol Number A021706). 
Toxicity Assay. The spleens of euthanized Golden Syrian hamsters were collected 
and cells were obtained using cell strainers. The cell preparation was then deprived 
of red blood cells using lysis buffer and spun in the centrifuge for 10mins, 1200RPM 
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at 4°C. The cells were washed in RPMI-5 [5% heat inactivated fetal calf serum, 1% 
penstrep (100μg/mL penicillin/streptomycin), 1% L-glutamate (100μg/mL L-
glutamate), RPMI-1640] twice, with the cells being spun between each wash. After 
the washes, the cells were counted and 106 cells were plated in RPMI-10 [10% heat 
inactivated fetal calf serum, 1% penstrep (100μg/mL penicillin/streptomycin), 1% L-
glutamate (100μg/mL L-glutamate), RPMI-1640] in each well of a 24-well plate. They 
were then exposed to a 50μg/mL dose of the pure Dalea pogonathera compounds. 
The positive control used was 5mM menadione, a known toxic compound, and the 
negative control was 2% DMSO.39 The experiment was run in triplicate with 
additional wells for the no-treatment and assay stain controls. The cells were 
incubated for 24 hours in 37°C, 5% CO2 and then prepared for flow cytometry 
analysis. They were stained with Invitrogen’s (Carlsbad, CA, USA) annexin V, Alexa 
Fluor 488 conjugate and propidium iodide and run through the Bio-Rad S3e Cell 
Sorter, collecting 50,000 events. The data was then compensated to minimize the 
overlapping of fluorophores, without which can cause the skewing of data due to 
the overexpression of fluorescence detected by the flow cytometer, and analyzed 
using FlowJo (Ashland, OR, USA) software. In FlowJo, the data used for further 
analysis was the percent of cells not dyed. The only cells of concern were those still 
living and cells dyed by either annexin V or propidium iodide are dead or in the 
process of dying. Following this, a one-way ANOVA with a post-hoc Tukey 
comparison was completed to determine toxicity by comparing the percentage of 
living cells from treated wells to the no-treatment control. 
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Ex Vivo Assay. 3-6 week old Golden Syrian hamsters were infected with 125 - 150 L3 
hookworms. During the 21-day infection, fecal collections were done to collect eggs 
to maintain the lifecycle of A. ceylanicum. After 21 days, the hamsters were 
euthanized via CO2 and the adult hookworms were removed from the small intestine 
and washed as previously described.34 Following the three 15 minute washes, the 
worms were incubated for 24 hours at 37°C, 5% CO2 in RPMI-1640 supplemented 
with 50% fetal bovine serum, 25μg/mL fungizone, and 20X penicillin/streptomycin. 
The hookworms were then plated in 24-well plates with 8 - 10 worms per well 
containing RPMI-1640, 50% fetal bovine serum, 25μg/mL fungizone, 20X 
penicillin/streptomycin, and 50μg/mL of the Dalea pogonathera compound being 
tested. To avoid bias, one worm was plated per well to each well before adding 
another, with the pattern of addition changing after each complete cycle. The 
positive control used was 25μg/mL tephrosin, a D. ornata compound that was 
shown to be highly active against adult hookworm34, and the negative control was 
1% DMSO. The plated worms were incubated at 37°C, 5% CO2 for 5 days with 
monitoring of mortality and motility daily. Motility was scored on a scale from 0 to 3, 
with 3 being normally active and 0 being dead. Percent mortality was calculated by 
counting the number of dead, 0 motility, worms. The resulting data were analyzed 
by one-way ANOVA with a post-hoc Tukey comparison to determine if the 
compound had any significant anthelmintic activity toward A.ceylanicum.   
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CHAPTER 3 
 
INVESTIGATION OF DALEA PARRYI (FABACEAE) METABOLITES FOR 
ANTHELMINTIC ACTIVITY AGAINST THE HUMAN PATHOGENIC 
HOOKWORM ANCYLOSTOMA CEYLANICUM. 
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ABSTRACT 
Hookworm, a parasite infecting a billion people worldwide causing iron-deficiency 
anemia, has begun to exhibit resistance to the current treatments used, the 
benzimidazoles mebendazole and albendazole. Due to this emerging resistance, the 
identification of new anthelmintic compounds is necessary. Using a combination of 
vacuum liquid chromatography and Sephadex LH-20 chromatography and other 
purification techniques, 13 pure compounds were isolated from Dalea parryi. The 
structures of these compounds were determined using HRESIMS, 13C NMR, and 
DEPT. Of the 13 compounds, only 12 had enough material for biological testing. The 
12 compounds were then tested for their toxicity towards lymphocytes obtained 
from Golden Syrian hamsters, Mesocricetus auratus. Using flow cytometry, the 
percentage of living cells from cells treated with 50μg/mL of compounds for 24 
hours was compared to cells with no treatment. Of the 12 compounds tested, 4 
were non-toxic, with the remaining 8 being significantly toxic. An ex vivo assay was 
also conducted to determine the presence of anthelmintic properties. Adult 
hookworms were exposed to 50μg/mL of compounds for 5 days, with motility and 
mortality being monitored daily. Unfortunately, none of the compounds were 
significantly active. 
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 Infecting around 1 billion people worldwide, hookworm is a parasitic worm 
endemic to Africa, Central and South America, and Southern and Southeast Asia 
causing iron-deficiency anemia.1,2 Although generally not fatal, chronic hookworm 
infection has been linked to an increased susceptibility to malaria, tuberculosis, and 
HIV, malnutrition, and physical and developmental stunting in children.1,2,3,4   
 Infection with hookworm occurs when exposed skin comes into contact with 
the infective stage larva (L3) located in the soil. L3 pierce the skin and use the host’s 
bloodstream to travel to the lungs. While in the lungs, the larva causes irritation, 
causing the host to cough and swallow, bringing the larva up the trachea and on to 
the small intestine. While in the small intestine, the hookworm mature into adults 
and attach to the small intestine, producing anticoagulants to continuously feed off 
blood.3,5-8 Although varying between species, about 0.02-0.2 mL of blood per worm 
per day is lost.3 This blood loss is responsible for the primary symptom of hookworm 
disease, iron-deficiency anemia.  
 Currently, following the deworming campaigns put forth by World Bank and 
the World Health Organization, the mass drug administration of the benzimidazoles 
albendazole and mebendazole are the usual treatment method for hookworm.10,11 
Previously recorded single-dose cure rates were as high as 100%; however, recent 
field studies refute that, with a cure rate of around 39-56%.9,12 Multiple dose 
regiments have more success, with a recent study suggesting a cure rate for soil-
transmitted helminths at 97.9%.13 Due to the increase in dosages, concerns have 
been raised about the selective pressure put on hookworm and the potential for 
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emerging resistance.14 Research in identifying new compounds with anthelmintic 
properties to eventually replace albendazole and mebendazole is integral to the 
continued treatment of hookworm disease. 
 Prior research using Dalea ornata was successful in identifying a compound 
with anthelmintic properties, tephrosin.15 However, tephrosin is toxic, so it is unable 
to be used as a therapy for now. To continue this work, pure compounds have been 
isolated from D. parryi, which has never been the subject of chemical investigation, 
and they have been evaluated for their toxicity and anthelmintic properties.  
  
 
Results and Discussion 
  
Chemical Investigation. The D. parryi crude methanol extracts were tested in an ex 
vivo bioassay that revealed apparent reductions in survival of A. ceylanicum 
hookworm.  At 100 g/mL, the crude extracts of aerial and root portions exhibited 
13% and 10% reductions in survival, respectively, at day 5 of the assay.  This level of 
activity is quite low compared to that of the crude extract of aerial parts of D. 
ornata; >50% reduction in survival on day 2.15 However, it was expected that activity 
would increase with further purification, as was the case in that prior study.  The 
crude extracts of D. parryi were each fractionated by silica gel vacuum liquid 
chromatography (VLC) and selected materials from these columns were further 
separated by Sephadex LH-20 chromatography.  Successive stages of purification of 
compounds over silica gel using linear gradients and step-gradient elution, resulted 
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in thirteen pure compounds (Figure 1). Of these compounds, 9 of them are new 
compounds.  
 
Figure 3.1. Structures of Compounds 1-12 Isolated from Dalea parryi. 
 
 
Biological Investigation. After the 24 hour incubation of cells exposed to 50μg/mL of 
compound, cell survival was determined using flow cytometry. The percentage of 
live cells in wells with exposure to compound was compared to the control cells 
exposed to 2% DMSO and were determined to be toxic if the difference, after a one-
way ANOVA with a post-hoc Tukey comparison, was statistically significant. Of the 
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12 compounds tested, compounds 4, 7, 9, and 13 were found to be non-toxic (Table 
1). The remaining compounds were toxic with compounds 5 and 6 having the most 
destructive effect on the splenocytes. Following the toxicity assay, an ex vivo with 
adult hookworm being exposed to 50μg/mL of compound for 5 days was conducted. 
The mortality and motility was monitored daily. Unfortunately, none of the 12 
compounds tested had any significant anthelmintic properties (Table 1). The lowest 
percent survival was compound 2 at 83 (+ 3.5). Although compounds 5 and 6 were 
very toxic to mammalian cells, the percent survival of hookworm was 96 (+ 5.3) and 
100 (+ 0.0) respectively, demonstrating that the toxicity toward splenocytes is not 
indicative of activity toward hookworm. 
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Table 3.1. Ex Vivo Anthelmintic Activity of D. parryi Compounds 1-2, 4-13 toward 
A. ceylanicum Hookworm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Controls of medium plus 1% DMSO all exhibited >95% survival  
at day five. Data are in mean values ± standard error (SE). 
b Flow cytometric analyses….+ error ranges. 
 
Although none of the compounds exhibited activity toward hookworm, the chemical 
investigation and identification of 9 new compounds is relevant in continued 
hookworm research. The methods used are applicable to similar projects and will 
hopefully serve its purpose in identifying new compounds to eventually replace 
albendazole and mebendazole.  
 
Experimental Section 
 
General Experimental Procedures. Melting points were measured on an SRS 
MPA160 DigiMelt apparatus. Optical rotations were recorded on a PerkinElmer 341 
polarimeter (Na lamp, 589 nm); concentrations are reported in g/100 mL. UV spectra 
Compound 
% Survival of A. 
ceylanicum relative to 
controla  
after five days of 
compound exposure 
at 50 μg/mL 
Toxicity expressed as 
negative or positive effects on 
splenocyte survival relative to 
100% survival (centerline)b 
 
1 93 (+ 6.7) 
 
2 83 (+ 3.5) 
4 88 (+ 7.0) 
5 96 (+ 5.3) 
6 100 (+ 0.0) 
7 88 (+ 4.6) 
8 100 (+ 0.0) 
9 100 (+ 0.0) 
10 100 (+ 0.0) 
11 100 (+ 0.0) 
12 88 (+ 7.0) 
13 88 (+ 7.0) 
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were recorded on an HP-Agilent 8453 photodiode array instrument. ECD spectra 
were obtained on an Aviv Biomedical, Inc. M400 circular dichroism spectrometer 
using dry MeOH as the solvent and a 0.1 cm path length quartz cuvette. IR spectra 
were recorded on a Bruker Alpha spectrometer with universal Alpha T attachment. 
NMR spectra were obtained on a Bruker Avance 400 MHz system with Topspin 1.3 
software. HRESIMS data were recorded on a Waters Q-TOF Premier hybrid mass 
spectrometer. A Waters Acquity UPLC was used to inject samples in 1:1 MeCN−H2O 
using flow injection analysis (100 μL/min) with no intervening column. Preparative 
linear gradient chromatography employed a custom two-chamber apparatus 
creating a continuous gradient, with gravity flow (~20 mL/min), over 70-230 mesh 
silica gel. This was connected to glass columns of varying sizes sealed with PTFE end-
fittings. Samples were preadsorbed onto silica gel in solution and evaporated to 
dryness prior to loading onto the column.  Eluting solvent percentages given (see 
‘Preparation of the extracts and compound purification’) represent estimates, for the 
sake of reproducibility, of the solvent compositions entering the column. Collection 
of 20 fractions (20 mL) for example, with a linear gradient of EtOAc (0-100%) in 
hexanes, will result in fraction 10 having a composition of ~50% EtOAc. Silica gel 
step-gradient columns also employed 60-100 mesh silica gel, and were run with 
preadsorbed samples. TLC plates (Sigma-Aldrich; silica gel 60, F254) were eluted with 
mixtures of MeOH in CH2Cl2 or of EtOAc in hexanes, and visualized with UV (254 nm) 
and the spray reagent vanillin/H2SO4 (1 g/100 mL w/v) followed by gentle heating. 
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Plant Material. Whole plants of D. parryi were collected by G. Belofsky, V. Belofsky, 
and L. Belofsky on April 22, 2015 about two miles up the East End Trail of McDowell 
Regional Park, Arizona, USA, at GPS coordinates N 33º 40.584′, W 111º 48.157′, alt. 
3404 ft.  A voucher specimen was authenticated by Dr. Tom Cottrell, Department of 
Biological Sciences, Central Washington University, and was deposited in the 
herbarium of the same department, accession no. 2015005GB.  Plant parts were 
separated, the roots were washed with distilled water and dried briefly, while aerial 
portions (leaves, stems, and flowers) were air-dried for several days.  Dry aerial 
portions and roots were powdered in a Waring blender and stored in vacuum-sealed 
plastic bags at -20 ºC prior to extraction. 
Preparation of Extracts and Compound Purification. Powdered roots (112 g) and 
aerial portions (1150 g) of D. parryi were extracted separately with 1.5 L and 7 L of 
MeOH, respectively, in a Waring blender for 2-3 min. The mixtures were each 
filtered, and the filtrates were evaporated under reduced pressure resulting in 14.9 
g of root extract and 135.0 g of aerial portion extract.  
The crude root extract was preadsorbed in MeOH solution onto ∼10 g of silica 
gel, the solvent removed under vacuum, and the resulting powder subjected to VLC 
over a prepacked column bed (10 × 5 cm; i.d. × h) of TLC-grade (230−400 mesh) silica 
gel. The column was eluted using a stepwise gradient of solvents beginning with 
hexanes (1 L) and continuing with mixtures (0.75 L each) of EtOAc in hexanes (20, 40, 
60, 80, and 100% EtOAc), followed by mixtures of MeOH in CH2Cl2 (2, 5, 8, 10, and 
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30% MeOH). Fractions 3-4 (2.14 g) from this column expressed both the heaviest 
weight and greatest mixture complexity by TLC analysis. These were further 
separated by Sephadex LH-20 (Sigma-Aldrich) column chromatography (2.5 × 50 cm) 
eluting with 1 L of 3:1:1 hexanes-toluene-MeOH, followed by 1 L of 100% MeOH at a 
flow rate of 0.3-0.5 mL/min with ~8 mL per fraction.  The glass column was equipped 
with a male luer tip for connection to a 100 tube, drop-counting fraction collector. 
Materials of similar composition as determined by TLC were pooled to give 49 
fractions.  Compounds 1-10 were all isolated upon elaboration of selected 
subfractions of these Sephadex LH-20 column fractions. 
The resulting Sephadex LH-20 fraction 3 (166 mg) was further purified over silica 
gel (10 × 2.5 cm) using a linear gradient (see ‘General Experimental Procedures’) of 
EtOAc (0-10%) in hexanes.  Fractions eluting with ~3-5% EtOAc resulted in 1 (89 mg).  
The combined Sephadex LH-20 fractions 5-6 (61 mg) were further purified over silica 
gel (5 × 2.5 cm) using a linear gradient of EtOAc (0-20%) in hexanes.  Fractions 
eluting with 20% EtOAc afforded 2 (23 mg).  Combined Sephadex LH-20 fractions 15-
21 (45 mg) were further purified over silica gel (9 × 2.5 cm) using a linear gradient of 
EtOAc (0-30%) in hexanes.  Fractions eluting with ~9-12% EtOAc resulted in 9 (8 mg), 
while later fractions from this column, eluting with 15-30% EtOAc were further 
purified over silica gel (1.5 × 5 cm) using a step-gradient (see ‘General Experimental 
Procedures’) of EtOAc (0-100%) in hexanes to yield 3 (6 mg) in one fraction, eluting 
with 30% EtOAc.  Fractions 45 and 46 of the Sephadex LH-20 column were combined 
(51 mg) and chromatographed over silica gel (8 × 2.5 cm) using a linear gradient of 
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EtOAc (0-50%) in hexanes. Final purification of fractions from this column (14 mg) 
that eluted with 25-30% EtOAc was achieved over silica gel (1.5 × 6 cm) using 
isocratic elution with 30% EtOAc in hexanes to provide 4 (7 mg).  Fraction 25 from 
the Sephadex LH-20 column (204 mg) was further purified over silica gel (10 × 2.5 
cm) using a linear gradient of EtOAc (0-15%) in hexanes.  Fractions eluting with ~8-
11% EtOAc resulted in 5 (139 mg).  Pooled fractions 38-40 from the Sephadex LH-20 
column (41 mg) were further purified over silica gel (7 × 2.5 cm) using a linear 
gradient of EtOAc (0-25%) in hexanes.  Fractions eluting with ~13-20% EtOAc 
resulted in 6 (11 mg).  Fraction 14 from the Sephadex LH-20 column (19 mg) was 
further purified over silica gel (8 × 1.1 cm) using a linear gradient of EtOAc (0-15%) in 
hexanes.  Fractions eluting with ~1-6% EtOAc afforded 7 (5 mg).  Fractions 42-44 of 
the Sephadex LH-20 column were combined (89 mg) and chromatographed over 
silica gel (10 × 2.5 cm) using a linear gradient of MeOH (0-6%) in CH2Cl2. Materials 
from this column that eluted with ~2-3% MeOH (75 mg) were chromatographed 
over silica gel (11 × 2.5 cm) using a linear gradient of EtOAc (0-30%) in hexanes.  
Fractions eluting with ~23-29% EtOAc (51 mg) were purified over silica gel using a 
step-gradient of EtOAc (0-30%) in hexanes to yield 8 (38 mg) in fractions eluting with 
20-22% EtOAc.  Compound 10 (10 mg) was obtained by chromatography of 
Sephadex column fraction 34 over silica gel (10 × 2.5 cm) using a linear gradient and 
eluting with ~11-14% EtOAc in hexanes. 
The crude extract of the aerial portions (135 g) was preadsorbed in MeOH 
solution onto ∼15 g of silica gel, the solvent removed under vacuum, and the 
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resulting powder subjected to VLC over a prepacked column bed (10 × 7 cm; i.d. × h) 
of TLC-grade (230−400 mesh) silica gel. The column was eluted using a stepwise 
gradient of solvents beginning with hexanes (2 L) and continuing with mixtures (1 L 
each) of EtOAc in hexanes (20, 40, 60, 80, and 100% EtOAc), followed by mixtures of 
MeOH in CH2Cl2 (2, 5, 8, 10, and 30% MeOH).  Fractions of interest 5-7 (2.7 g) from 
this column were further separated by Sephadex LH-20 column chromatography (2.5 
× 75 cm) in an otherwise identical manner to that described above for the root VLC 
fractions, resulting in 25 fractions.   Compound 11 (6 mg) was obtained by 
chromatography of Sephadex column fraction 14 (64 mg) over silica gel (7 × 2.5 cm) 
using a linear gradient and eluting with ~42-48% EtOAc in hexanes.  A VLC column of 
Sephadex fraction 23 (85 mg) over silica gel (5 × 3.5 cm) eluting with 100 mL 
fractions of increasing EtOAc in hexane afforded 12 (16 mg) in a fraction that eluted 
with 75% EtOAc.  Sephadex fractions 15-16 (97 mg) were chromatographed over 
silica gel (12 × 2.5 cm) using a linear gradient of 0-6% MeOH in CH2Cl2.  Material that 
eluted with ~3% MeOH was then purified over silica gel (4.5 × 1.5 cm) using a step-
gradient of 0-100% EtOAc in hexanes.  Fractions eluting with 60-70% EtOAc 
consisted of 13 (5 mg). 
Anthelmintic and Toxicity Assays. Syrian hamsters (Mesocricetus auratus) were 
used for all animal work including maintenance of the hookworm Ancylostoma 
ceylanicum in the laboratory, ex vivo and toxicity assays. Hamsters were either 
purchased from Simonsen Lab (Gilroy, CA, USA) or second generation bred at the 
Central Washington University animal facility. Animals were housed in 12:12 hour 
 40 
light: dark and temperature-controlled conditions at the Central Washington 
University (CWU) animal facility.  Animal handling and experimental conditions 
followed protocols approved by the CWU Institutional Animal Care and Use 
Committee (Protocol Numbers A111608, A111609, and A021706). For each round of 
the ex vivo assay, 20-25 hamsters were orally infected with 125-150 L3 (infectious 
stage) hookworm larvae. Initial A. ceylanicum larvae were generously provided by 
Dr. Michael Cappello (Yale School of Medicine, New Haven, CT). On day 21 PI, the 
fecal material was gathered, the hamsters were euthanized and the small intestines 
were collected. The fecal material contains hookworm eggs and was used for the 
production of more infectious larvae for subsequent experiments. Adult worms 
were harvested from the intestine using tweezers under a dissecting microscope and 
processed as previously described.15 Briefly, worms were placed in a Petri dish 
containing phosphate buffer saline (PBS) with 20 X penicillin/streptomycin 
(pen/strep), and fungizone (25 μg/mL). The worms were washed three times in RPMI 
medium containing fungizone (25 μg/mL) and 20X penicillin/streptomycin. After an 
overnight incubation (37oC; 5% CO2) in RPMI medium supplemented with fungizone 
(25 μg/mL) and 20X penicillin/streptomycin, and 50% fetal bovine serum (FBS), 
active worms were randomly placed in a 24-well tissue culture plate. Each wells 
contained 8-10 worms. Each compound was tested in triplicate. 1% DMSO was used 
in negative control wells while tephrosin, a highly active compound isolated earlier 
from D. ornata was used as positive control.15  All the compounds were tested at 50 
μg/mL except the tephrosin positive control that was tested at 25 μg/mL. Plant 
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materials dissolved in 100% DMSO were diluted in RPMI, fungizone (25 μg/mL), 20X 
penicillin/streptomycin medium, and 50% FBS medium to reach a final concentration 
of 1% DMSO. Plates were checked daily for 5 days to determine the percent survival 
of worms. Dead and living worms were counted to calculate percent survival.  
In order to evaluate the potential safety of compounds extracted to mammalians, 
toxicity assays were conducted. Splenocytes from Golden Syrian hamsters were 
collected and plated in RPMI-10 (RPMI medium supplemented with 10% heat 
inactivated fetal calf serum, penicillin/streptomycin and L-glutamine) in a 24-well 
plate. Cells were then exposed to 50μg/mL of the pure Dalea parryi compounds. The 
positive control used was 5mM menadione, This compound has been shown to be 
toxic to cells by inducing DNA damage via reactive oxygen species formation.16 2% 
DMSO was used negative control in the toxicity evaluations. Samples and controls 
were run in triplicate. Each well contained 106 splenocytes. The cells were incubated 
for 24 hours at 37°C, 5% CO2 and then prepared for flow cytometry. They were 
stained with annexin V, Alexa Fluor 488 conjugate and propidium iodide (Thermo 
Fischer Scientific, Waltham, MA). Stained cell parameters were acquired by flow 
cytometry using the Bio-Rad S3e Cell Sorter (Bio-Rad Laboratories, Hercules, CA). 
The flow cytometry data were analyzed and analyzed using the FlowJo software 
program (Treestar, Ashland, OR).  
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